Payment overview · 2025
General Payments
$406.88
16 reported records · 3 companies
Healthcare provider profile · identity verified
Anthony William Freda, DO
Allopathic & Osteopathic Physicians|Internal Medicine · PECKVILLE, PA · NPI 1598745499
Verified facts
What the public records show
CMS Open Payments records show Anthony William Freda, DO received $406.88 in general payments during 2025 across 16 reported records.
Amgen Inc. accounted for 42.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 7 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 62 claims for Synthroid by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 68 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $170.75 | 42.0% | 11 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $145.02 | 35.6% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $91.11 | 22.4% | 3 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $406.88 | 16 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $170.75 | 11 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $91.11 | 3 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $67.05 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $45.75 | 10 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $20.02 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $20.02 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 68 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
62 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
68 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 827 | 167 |
| Atorvastatin Calcium | Atorvastatin Calcium | 775 | 165 |
| Metoprolol Succinate | Metoprolol Succinate | 641 | 116 |
| Lisinopril | Lisinopril | 574 | 130 |
| Levothyroxine Sodium | Levothyroxine Sodium | 571 | 111 |
| Omeprazole | Omeprazole | 494 | 94 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 315 | 72 |
| Pantoprazole Sodium | Pantoprazole Sodium | 309 | 58 |
| Furosemide | Furosemide | 289 | 59 |
| Escitalopram Oxalate | Escitalopram Oxalate | 250 | 42 |
| Eliquis | Apixaban | 238 | 38 |
| Metformin Hcl | Metformin Hcl | 236 | 53 |
| Simvastatin | Simvastatin | 221 | 51 |
| Valsartan | Valsartan | 206 | 47 |
| Tamsulosin Hcl | Tamsulosin Hcl | 187 | 37 |
| Famotidine | Famotidine | 184 | 27 |
| Gabapentin | Gabapentin | 157 | 26 |
| Alprazolam | Alprazolam | 154 | 42 |
| Duloxetine Hcl | Duloxetine Hcl | 148 | 27 |
| Losartan Potassium | Losartan Potassium | 146 | 33 |
| Citalopram Hbr | Citalopram Hydrobromide | 126 | 22 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 108 | 16 |
| Donepezil Hcl | Donepezil Hcl | 106 | 19 |
| Metoprolol Tartrate | Metoprolol Tartrate | 103 | 26 |
| Allopurinol | Allopurinol | 101 | 22 |
| Quetiapine Fumarate | Quetiapine Fumarate | 97 | 16 |
| Memantine Hcl | Memantine Hcl | 96 | 13 |
| Clopidogrel | Clopidogrel Bisulfate | 94 | 17 |
| Finasteride | Finasteride | 94 | 21 |
| Fluticasone Propionate | Fluticasone Propionate | 91 | 28 |
| Carvedilol | Carvedilol | 89 | 17 |
| Metformin Hcl Er | Metformin Hcl | 89 | 16 |
| Irbesartan | Irbesartan | 88 | 17 |
| Jardiance | Empagliflozin | 87 | 17 |
| Prednisone | Prednisone | 86 | 45 |
| Potassium Chloride | Potassium Chloride | 84 | 19 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 84 | suppressed |
| Januvia | Sitagliptin Phosphate | 82 | 13 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 79 | 37 |
| Farxiga | Dapagliflozin Propanediol | 72 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 70 | 14 |
| Ozempic | Semaglutide | 68 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 66 | 13 |
| Montelukast Sodium | Montelukast Sodium | 65 | 13 |
| Trazodone Hcl | Trazodone Hcl | 64 | suppressed |
| Synthroid | Levothyroxine Sodium | 62 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 58 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 57 | 11 |
| Solifenacin Succinate | Solifenacin Succinate | 55 | 11 |
| Diltiazem 24hr Er | Diltiazem Hcl | 54 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 53 | suppressed |
| Meloxicam | Meloxicam | 51 | 12 |
| Divalproex Sodium | Divalproex Sodium | 50 | 12 |
| Fluoxetine Hcl | Fluoxetine Hcl | 50 | suppressed |
| Bupropion Xl | Bupropion Hcl | 49 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 49 | 11 |
| Tradjenta | Linagliptin | 49 | suppressed |
| Mounjaro | Tirzepatide | 48 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 46 | suppressed |
| Ezetimibe | Ezetimibe | 46 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 45 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 42 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 41 | suppressed |
| Mirtazapine | Mirtazapine | 40 | suppressed |
| Sucralfate | Sucralfate | 40 | suppressed |
| Xarelto | Rivaroxaban | 40 | suppressed |
| Baclofen | Baclofen | 38 | suppressed |
| Clonazepam | Clonazepam | 38 | 11 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 38 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 38 | 12 |
| Aripiprazole | Aripiprazole | 37 | suppressed |
| Olanzapine | Olanzapine | 37 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 36 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 35 | suppressed |
| Methylprednisolone | Methylprednisolone | 35 | 30 |
| Repatha Sureclick | Evolocumab | 35 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 34 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 34 | 15 |
| Breo Ellipta | Fluticasone/Vilanterol | 34 | suppressed |
| Cephalexin | Cephalexin | 33 | 21 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 33 | suppressed |
| Atenolol | Atenolol | 32 | 11 |
| Celecoxib | Celecoxib | 31 | 11 |
| Dutasteride | Dutasteride | 31 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 31 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 31 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 31 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 30 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 30 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 29 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 29 | suppressed |
| Levetiracetam | Levetiracetam | 28 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 26 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 26 | suppressed |
| Loperamide | Loperamide Hcl | 26 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 26 | suppressed |
| Azithromycin | Azithromycin | 25 | 24 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 25 | 21 |
| Enalapril Maleate | Enalapril Maleate | 25 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 25 | suppressed |
| Nystatin | Nystatin | 25 | 16 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 24 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 23 | 20 |
| Glimepiride | Glimepiride | 23 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 23 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 22 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 22 | 11 |
| Hydralazine Hcl | Hydralazine Hcl | 22 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 22 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 22 | suppressed |
| Torsemide | Torsemide | 22 | suppressed |
| Levofloxacin | Levofloxacin | 21 | 19 |
| Lorazepam | Lorazepam | 21 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 21 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 20 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 20 | suppressed |
| Invokana | Canagliflozin | 19 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 19 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 19 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 18 | suppressed |
| Spironolactone | Spironolactone | 18 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 18 | 13 |
| Trulicity | Dulaglutide | 18 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 17 | 16 |
| Ibuprofen | Ibuprofen | 17 | suppressed |
| Pregabalin | Pregabalin | 17 | suppressed |
| Cetirizine Hcl | Cetirizine Hcl | 16 | suppressed |
| Felodipine Er | Felodipine | 16 | suppressed |
| Folic Acid | Folic Acid | 16 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 16 | 11 |
| Cholestyramine Light | Cholestyramine | 14 | suppressed |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 14 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 14 | suppressed |
| Lamotrigine | Lamotrigine | 14 | suppressed |
| Amoxicillin | Amoxicillin | 13 | suppressed |
| Dextrose 5%-0.9% Nacl | Dextrose 5 % And 0.9 % Nacl | 13 | suppressed |
| Diazepam | Diazepam | 13 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 13 | suppressed |
| Ethosuximide | Ethosuximide | 13 | suppressed |
| Galantamine Hbr | Galantamine Hbr | 13 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 13 | suppressed |
| Lansoprazole | Lansoprazole | 13 | suppressed |
| Lidocaine | Lidocaine | 13 | suppressed |
| Risperidone | Risperidone | 13 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 13 | suppressed |
| Azelastine-Fluticasone | Azelastine/Fluticasone | 12 | suppressed |
| Dilantin | Phenytoin Sodium Extended | 12 | suppressed |
| Novolog Flexpen | Insulin Aspart | 12 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 12 | 12 |
| Pentoxifylline | Pentoxifylline | 12 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 12 | suppressed |
| Rexulti | Brexpiprazole | 12 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 12 | suppressed |
| Tobramycin | Tobramycin | 12 | 12 |
| Clonidine | Clonidine | 11 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 11 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 11 | suppressed |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 11 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 11 | suppressed |
| Ramipril | Ramipril | 11 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $406.88 · 16 records | Amgen Inc. | OTEZLA, Ozempic, QULIPTA, REPATHA, Rybelsus, UBRELVY, Wegovy | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error